Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2019 Jul 17;11(501):eaau0416.
doi: 10.1126/scitranslmed.aau0416.

Comment on "PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL human leukemia"

Danilo Perrotti  1   2 , Anupriya Agarwal  3 , Claire M Lucas  4 , Goutham Narla  5 , Paolo Neviani  6 , Maria D Odero  7 , Peter P Ruvolo  8 , Nicole M Verrills  9
Affiliations
Comment

Comment on "PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL human leukemia"

Danilo Perrotti et al. Sci Transl Med. .

Abstract

LB100 does not sensitize CML stem cells to tyrosine kinase inhibitor-induced apoptosis.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.. Effects of protein phosphatase 2A–activating drug and protein phosphatase 2A–inhibiting drug in chronic myeloid leukemia.
(A) Hematopoietic stem cell (HSC) and progenitor activity after protein phosphatase 2A–activating drug (PAD) or protein phosphatase 2A–inhibiting drug (PID) treatment. (1) Eight PADs were independently tested in nine laboratories. (2) Average of data from Perrotti group’s publications. (3) PAD-induced apoptosis also in BCR-ABL1T315I chronic myeloid leukemia (CML). (4) PID values are from Lai et al. (1). (5) FTY720 and derivatives increase bone marrow (BM) homing of normal but not tumor HSCs. (B) Effects of LB100 on CML cell proliferation and survival. Data are from figures 6 and 8 and figure S8 of Lai et al. (1). TKI, tyrosine kinase inhibitor; CFC, colony-forming cell; LTC-IC, long-term culture-initiating cell; NR, nonresponder; N/A, not applicable; N.S, nonsignificant differences; wk, weeks; DAS, dasatinib; RT-PCR, reverse transcription polymerase chain reaction. NBM, normal bone marrow; CFSEmax, maximum staining with carboxyfluorescein succinimidyl ester; hLSC, human leukemia stem cell; CMPs, common myeloid progenitors; LSK, lineage-negative Sca+ Kit+; DA, dasatinib.
See this image and copyright information in PMC

Comment in

Comment on

References

    1. Lai D, Chen M, Su J, Liu X, Rothe K, Hu K, Forrest DL, Eaves CJ, Morin GB, Jiang X, PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL+ human leukemia. Sci. Transl. Med 10, eaan8735 (2018). - PubMed
    1. Neviani P, Harb JG, Oaks JJ, Santhanam R, Walker CJ, Ellis JJ, Ferenchak G, Dorrance M, Paisie CA, Eiring AM, Ma Y, Mao HC, Zhang B, Wunderlich M, May PC, Sun C, Saddoughi SA, Bielawski J, Blum W, Klisovic RB, Solt JA, Byrd JC, Volinia S, Cortes J, Huettner CS, Koschmieder S, Holyoake TL, Devine S, Caligiuri MA, Croce CM, Garzon R, Ogretmen B, Arlinghaus RB, Chen CS, Bittman R, Hokland P, Roy DC, Milojkovic D, Apperley J, Goldman JM, Reid A, Mulloy JC, Bhatia R, Marcucci G, Perrotti D, PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. J. Clin. Invest 123, 4144–4157 (2013). - PMC - PubMed
    1. Ciccone M, Calin GA, Perrotti D, From the biology of PP2A to the PADs for therapy of hematologic malignancies. Front. Oncol 5, 21 (2015). - PMC - PubMed
    1. Chung V, Mansfield AS, Braiteh F, Richards D, Durivage H, Ungerleider RS, Johnson F, Kovach JS, Safety, tolerability, and preliminary activity of LB-100, an inhibitor of protein phosphatase 2A, in patients with relapsed solid tumors: An open-label, dose escalation, first-in-human, phase I trial. Clin. Cancer Res 23, 3277–3284 (2017). - PubMed
    1. Zhou LL, Zhao Y, Ringrose A, DeGeer D, Kennah E, Lin AE-J, Sheng G, Li X-J, Turhan A, Jiang X, AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells. J. Exp. Med 205, 2657–2671 (2008). - PMC - PubMed

MeSH terms

Substances